Payment overview · 2025
General Payments
$51.47
2 reported records · 2 companies
Healthcare provider profile · identity verified
Maritza Laguna, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1417928946
Verified facts
What the public records show
CMS Open Payments records show Maritza Laguna, M.D. received $51.47 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.88 | 54.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.59 | 45.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $51.47 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 159 |
| Lisinopril | Lisinopril | 399 | 109 |
| Metformin Hcl | Metformin Hcl | 294 | 84 |
| Omeprazole | Omeprazole | 277 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 60 |
| Losartan Potassium | Losartan Potassium | 198 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 49 |
| Chlorthalidone | Chlorthalidone | 185 | 57 |
| Metformin Hcl Er | Metformin Hcl | 166 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 51 |
| Gabapentin | Gabapentin | 139 | 39 |
| Carvedilol | Carvedilol | 137 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 38 |
| Potassium Chloride | Potassium Chloride | 122 | 42 |
| Mirtazapine | Mirtazapine | 121 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 33 |
| Jardiance | Empagliflozin | 110 | 34 |
| Alendronate Sodium | Alendronate Sodium | 106 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 26 |
| Furosemide | Furosemide | 99 | 25 |
| Valsartan | Valsartan | 99 | 31 |
| Trulicity | Dulaglutide | 96 | 22 |
| Simvastatin | Simvastatin | 89 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 15 |
| Finasteride | Finasteride | 80 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 25 |
| Allopurinol | Allopurinol | 75 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 15 |
| Linzess | Linaclotide | 65 | 14 |
| Spironolactone | Spironolactone | 64 | 20 |
| Ozempic | Semaglutide | 60 | 11 |
| Eliquis | Apixaban | 59 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 14 |
| Tradjenta | Linagliptin | 53 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 14 |
| Montelukast Sodium | Montelukast Sodium | 45 | 16 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 15 |
| Ibuprofen | Ibuprofen | 41 | 28 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 18 |
| Ammonium Lactate | Ammonium Lactate | 36 | 15 |
| Enalapril Maleate | Enalapril Maleate | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 12 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $51.47 · 2 records | GlaxoSmithKline, LLC. | Cologuard Collection Kit, FLULAVAL QUADRIVALENT, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error